1 0

    FDA Summary Basis of Approval – CMC Section for Eribulin Mesylate Injection 1 mg/2 mL (Application A217250, Approved October 1, 2024)

    FDA Summary Basis of Approval – CMC Section for Eribulin Mesylate Injection 1 mg/2 mL (Application A217250, Approved October 1, 2024)

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request Contents: Summary Basis of Approval – CMC section for Drug Substance of Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL), Application A217250, approved October 1, 2024
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details